These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 24234332)
1. High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder. Zhang Z; Zhang G; Kong C Tumour Biol; 2014 Mar; 35(3):2503-12. PubMed ID: 24234332 [TBL] [Abstract][Full Text] [Related]
2. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder. Yan Y; Yang FQ; Zhang HM; Li J; Li W; Wang GC; Che JP; Zheng JH; Liu M Int J Clin Exp Pathol; 2014; 7(7):4231-8. PubMed ID: 25120803 [TBL] [Abstract][Full Text] [Related]
3. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Zhang Z; Zhang G; Kong C Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978 [TBL] [Abstract][Full Text] [Related]
4. Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. Yang FQ; Huang JH; Liu M; Yang FP; Li W; Wang GC; Che JP; Zheng JH Int J Clin Exp Pathol; 2014; 7(1):340-7. PubMed ID: 24427355 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412 [TBL] [Abstract][Full Text] [Related]
6. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Xue Y; Wu G; Wang X; Zou X; Zhang G; Xiao R; Yuan Y; Long D; Yang J; Wu Y; Xu H; Liu F; Liu M Med Oncol; 2013 Mar; 30(1):406. PubMed ID: 23275123 [TBL] [Abstract][Full Text] [Related]
7. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105 [TBL] [Abstract][Full Text] [Related]
8. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Xue YJ; Lu Q; Sun ZX Med Oncol; 2011 Dec; 28(4):1363-72. PubMed ID: 20509007 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features. Yu XY; Zhang Z; Zhang GJ; Guo KF; Kong CZ Asian Pac J Cancer Prev; 2012; 13(3):931-5. PubMed ID: 22631674 [TBL] [Abstract][Full Text] [Related]
10. CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Fontanini G Hum Pathol; 2007 Oct; 38(10):1563-8. PubMed ID: 17651784 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer. Ruan J; Wei B; Xu Z; Yang S; Zhou Y; Yu M; Liang J; Jin K; Huang X; Lu P; Cheng H Med Oncol; 2013 Mar; 30(1):445. PubMed ID: 23307254 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. Wang Z; Trope CG; Flørenes VA; Suo Z; Nesland JM; Holm R BMC Cancer; 2010 May; 10():233. PubMed ID: 20500813 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Takemasa I; Yamamoto H; Sekimoto M; Ohue M; Noura S; Miyake Y; Matsumoto T; Aihara T; Tomita N; Tamaki Y; Sakita I; Kikkawa N; Matsuura N; Shiozaki H; Monden M Cancer Res; 2000 Jun; 60(11):3043-50. PubMed ID: 10850455 [TBL] [Abstract][Full Text] [Related]
14. Expression of beclin 1 in bladder cancer and its clinical significance. Liu GH; Zhong Q; Ye YL; Wang HB; Hu LJ; Qin ZK; Zeng MS; Zeng BH Int J Biol Markers; 2013 Apr; 28(1):56-62. PubMed ID: 23125008 [TBL] [Abstract][Full Text] [Related]
15. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder. Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270 [TBL] [Abstract][Full Text] [Related]
16. Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladder. Suárez-Bonnet A; Herráez P; Aguirre M; Suárez-Bonnet E; Andrada M; Rodríguez F; Espinosa de Los Monteros A Urol Oncol; 2015 Jul; 33(7):332.e1-7. PubMed ID: 25979650 [TBL] [Abstract][Full Text] [Related]
17. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer. Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769 [TBL] [Abstract][Full Text] [Related]
18. Binding of 14-3-3beta but not 14-3-3sigma controls the cytoplasmic localization of CDC25B: binding site preferences of 14-3-3 subtypes and the subcellular localization of CDC25B. Uchida S; Kuma A; Ohtsubo M; Shimura M; Hirata M; Nakagama H; Matsunaga T; Ishizaka Y; Yamashita K J Cell Sci; 2004 Jun; 117(Pt 14):3011-20. PubMed ID: 15173315 [TBL] [Abstract][Full Text] [Related]
19. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Liu JY; Qian D; He LR; Li YH; Liao YJ; Mai SJ; Tian XP; Liu YH; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D Mol Cancer; 2013 Nov; 12(1):148. PubMed ID: 24268029 [TBL] [Abstract][Full Text] [Related]
20. 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma. Chan SY; To KF; Leung SF; Yip WW; Mak MK; Chung GT; Lo KW Oncol Rep; 2010 Oct; 24(4):949-55. PubMed ID: 20811675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]